Research - Infectious Diseases Fellowship

Research - Infectious Diseases Fellowship

Cooper Research Institutedoctors in research lab

Through basic and clinical research, faculty at Cooper University Health Care are bringing scientific discoveries to life with access to cutting-edge treatments in fields such as cancer, cardiology, critical care, diabetes and gene therapy. Cooper faculty members conduct National Institutes of Health (NIH) and industry-sponsored clinical trials each year in South Jersey, many of which are only available at Cooper. Annual NIH and federal grants together with aggregate research funding makes Cooper one of the top regional medical campuses in the country. Past research by Cooper faculty has led to new standards of care and novel therapies in fields such as cancer, cardiology, surgery and orthopaedics.

Coriell Institute of Medical Research

The Coriell Institute for Medical Research is an independent, not-for-profit research organization dedicated to understanding human genetic diseases and providing the highest quality genetic resources. Its affiliation with Cooper University Health Care provides an excellent opportunity to our residents to participate in a variety of basic science research.

Recent Fellow Scholarly Activity

Ng K, Schorr C, Reboli AC, Zanotti S, Tsigrelis C. Incidence and mortality of sepsis, severe sepsis, and septic shock in intensive care unit patients with candidemia [Published online ahead of print March 26, 2015]. Infect Dis (Lond). 2015 Aug;47(8):584-587. doi: 10.3109/23744235.2015.1028100.

Ng K, Tsigrels C, Reboli AC, et al. Incidence study of sepsis, severe sepsis, and septic shock in patients with candidemia in an ICU setting. Oral presentation at:  Infectious Diseases Society of New Jersey; June, 2014. 

Rasool M, Knob C, Fraimow H. High prevalence of Panton-Valentine Leukocidin in methicillin-susceptible Staphylococcus aureus in Camden, NJ. Oral presentation at: Infectious Diseases Society of New Jersey; June, 2014; and at the Meeting of the Infectious Diseases Society of America – IDWeek; October, 2014, Philadelphia, PA.

Chasanov WM, Trager JD, Jagga S, et al. MDR Gram Negative Bacteria in the ICU. Oral presentation at: Infectious Diseases Society of New Jersey; June, 2015; Annual Camden Scholars’ Forum; February, 2015; and the University of Pennsylvania ID Forum; April, 2015.

Gabriel N, Nahra, R. Prednisone in septic shock in patients with HIV.

Kade H, Gray A, de la Torre P. Anal Paps in Men Who Have Sex with Men in the EIP Clinic. Oral presentation at: Infectious Diseases Society of New Jersey; June, 2015. 

Recent Faculty Scholarly Activity

Pola de la Torre, MD

Hafkin J, Osborn M, Localio R, Amorosa V, Kostman J, Stern J, de la Torre P, et. al. Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-coinfected patients initiating tenofovir-based therapy.  J Viral Hepat. 2014 Apr;21(4):288-296.

de la Torre P, Reboli AC. Micafungin: an evidence-based review of its place in therapy. Core Evid. 2014 Feb 25; 9:27-29.

de la Torre P, George J, Baxter J.  Nucleoside-sparing antiretroviral regimens. Curr Infect Dis Rep. 2014;16:410-420.

de la Torre P (Principal Investigator). Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Patients with Latent Tuberculosis Infection. 2012-2014. ACTG Protocol 5279. Available from: https://clinicaltrials.gov/ct2/show/NCT01404312. ClinicalTrials.gov Identifier: NCT01404312.

de la Torre P (Principal Investigator). A Prospective, Phase III, Open-Label Study of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects (BIRTH). 2012-2014. ACTG Protocol 5294. Available from: https://clinicaltrials.gov/ct2/show/NCT01482767. ClinicalTrials.gov Identifier: NCT01482767

de la Torre P (Principal Investigator). Grant Support: Special Projects of National Significance Program (SPNS), Hepatitis C Treatment Expansion Initiative – HRSA-10-090.  $160,000. September 2011- August 2013.

John D. Baxter, MD

de la Torre P, George J, Baxter JD. Nucleoside-sparing antiretroviral regimens. Current Infectious Disease Reports. 2014 June; 16:410. 

Baxter JD, Chasanov WM, Adams JL. An Update on HIV-1 Protease Inhibitor Resistance. J AIDS & Clin Res 2016 May: 7(6):1-7.

Baxter JD, Dunn D, White E, Sharma S, Geretti AM, Kozal M, Johnson M, Jacoby S, Llibre JM, Lundgren J. Global HIV-1 Transmitted Drug Resistance in the START Study. HIV Medicine. 2015 Feb;16:77–87. doi: 10.1111/hiv.12236  

Baxter JD (Principal Investigator). START – Strategic Timing of Antiretroviral Treatment - purpose of this randomized INSIGHT study is to determine whether immediate initiation of antiretroviral treatment (ART) is superior to deferral of ART until the CD4+ declines below 350 cells/mm3 in terms of morbidity and mortality in HIV-1 infected persons who are antiretroviral naïve with a CD4+ count above 500 cells/mm3. Available at: https://clinicaltrials.gov/show/NCT00867048. ClinicalTrials.gov Identifier: NCT00867048

Baxter JD (Principal Investigator). A5275. A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals with Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL. Available at: https://clinicaltrials.gov/ct2/show/NCT01351025. ClinicalTrials.gov Identifier: NCT01351025

Baxter JD (Principal Investigator). The Optimized Treatment that Includes or Omits NRTIs (OPTIONS) Trial: Randomized Strategy Study for HIV-1-Infected Treatment-Experienced Subjects Using the cPSS to Select an Effective Regimen. Available at: https://clinicaltrials.gov/ct2/show/NCT00537394. ClinicalTrials.gov Identifier: NCT00537394

Baxter, JD (Principal Investigator). Boehringer Ingelheim. 1220.19. Safety and Efficacy of 240 mg BI 201335 once daily in combination with pegylated interferon alpha 2a and ribavirin for treatment of chronic Hepatitis C (HCV) genotype 1 infection in HIV/HCV-co-infected patients. Available at: https://clinicaltrials.gov/ct2/show/NCT01399619. ClinicalTrials.gov Identifier: NCT01399619

Baxter, JD (Principal Investigator). GlaxoSmithKline. Study #114083. Long-term roll over study for Phase 2b multicenter therapeutic study of F4co/AS01b vaccine in HIV-1 infected persons. Available at: https://clinicaltrials.gov/ct2/show/NCT01376310. ClinicalTrials.gov Identifier: NCT01376310

Henry S. Fraimow, MD

Sabbah MA, Schorr C, Czosnowski QA, Hunter K, Torjman MC, Fraimow HS, Zanotti S, Tsigrelis C. Risk of Clostridium Difficile Infection in Intensive Care Unit Patients with Sepsis Exposed to Metronidazole. Infect. Dis (Lond). 2015, Apr; 47(4):197-202

George J, Czosnowski Q, Fraimow H, Beekman SE, Polgreen PM. Infectious Diseases Physician’s Approaches to Antiretroviral Therapy in HIV/AIDS patients admitted to an Intensive Care Unit: An Emerging Infections Network Survey [Published online ahead of print April 2013]. Infect Dis Clin Pract. 2014 March;22(2):78-84.

Fraimow HS. Chipping Away at Unnecessary Antibiotic Use in the Intensive Care Unit, One Day and One Study at a Time [editorial]. Crit Care Med. 2013;41(10):2447-8.

Pulimamidi S, Caputo FJ, Fraimow HS, Nahra R, Tsigrelis C. Salmonella aortitis treated with endovascular aortic repair [Published online ahead of print December 25, 2013]. Ann Vasc Surg. 2014 Jul;28(5):1314.e5-10. doi: 10.1016/j.avsg.2013.09.015.; pii: S0890-5096.

Fraimow HS, Reboli AR. Specific Infections with Critical Care Implications. In: Parrillo JE, Dellinger RP, eds. Critical Care Medicine: Principles of Diagnosis and Management in the Adult, 4th ed. Philadelphia, PA: Saunders Elsevier; 2013: 1133-1161.

Nahra R, Fraimow HS. Resistant Gram Negative Infections. Crit Care Clinics. 2013;29(4):895-921

Sabbah MA, Schorr C, Czosnowski QA, Hunter K, Torjman MC, Fraimow HS, Zanotti S, Tsigrelis C.Risk of Clostridium difficile infection in intensive care unit patients with sepsis exposed to metronidazole [Published online ahead of print January 22, 2015.]. Infect Dis (Lond). 2015 Apr;47(4):197-202. doi: 0.3109/00365548.2014.978890.

Rose Kim, MD

Kim R (Principal Investigator). ACTG A5257: A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1 Infected Volunteers (The ARDENT Study: Atazanavir,Raltegravir, or Darunavir with Emtricitabine/Tenofovir for Naive Treatment). Available at: https://clinicaltrials.gov/ct2/show/NCT00811954. ClinicalTrials.gov Identifier: NCT00811954 Preliminary results presented at: Conference on Retroviruses and Opportunistic Infections (CROI); March, 2014; Boston, MA.

Kim R (Principal Investigator). ACTG A5272: Oral HPV Shedding and Oral Warts after Initiation of Antiretroviral Therapy. Available at: https://clinicaltrials.gov/ct2/show/NCT01029249. ClinicalTrials.gov Identifier: NCT01029249

Kim R (Principal Investigator). ACTG A5303: A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected with R5-Tropic HIV-1. Available at: https://clinicaltrials.gov/ct2/show/NCT01400412. ClinicalTrials.gov Identifier: NCT01400412

Kim R (Principal Investigator). Quality of Life of HIV-infected Patients Switched to Raltegravir Versus other Antiretroviral Regimens. Available at: https://clinicaltrials.gov/ct2/show/NCT01814722. ClinicalTrials.gov Identifier: NCT01814722

Kim R, Reboli AR. Other Coryneform Bacteria and Rhodococci. In: Mandell: Principles and Practice of Infectious Diseases, 8th ed. Vol 2. Philadelphia, PA: Saunders Elsevier; 2015: 2373-2382.

Raquel Nahra, MD

Nahra R, Fraimow HS. Resistant Gram Negative Infections. Crit Care Clinics. 2013;29(4):895-921

Chasanov W (Principal Investigator), Trager JD, Jagga S, Zarbiv S, Nahra, R (Co-investigators). Multiple Drug Resistant Bacteria in the ICU. Oral presentation at: Infectious Diseases Society of New Jersey; June, 2014; and First Annual Camden Scholars' Forum; 2014.

Gabriel N (Principal Investigator), Nahra R (Co-investigator). Prednisone in septic shock in patients with HIV.

Nahra R (Principal Investigator). FLU 003 – An observational study of hospitalized patients with influenza – this INSIGHT study collects influenza isolates and material for genetic testing in individuals with severe influenza infection.

Nahra R (Principal Investigator). Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot). The Journal Of Infectious Diseases, 2016 Feb;213(4):574-578.

Rosalie Pepe, MD

George J, Pepe R. Antimicrobial agent tables. In: Clinical Infectious Disease, 2nd ed. Cambridge University Press; 2015:211

Pepe R (Principal Investigator).  ACTG 5332: A Randomized Trial to Prevent Vascular Events in HIV – REPRIEVE., Available at: https://clinicaltrials.gov/ct2/show/NCT02344290. ClinicalTrials.gov Identifier: NCT02344290

Dana D. Byrne, MD

Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KB, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Russell Localio A, Lo Re V 3rd. Risk of Hip Fracture Associated with Untreated and Treated Chronic Hepatitis B Virus Infection. Journal of Hepatology. 2014 Aug;61(2):210-8

Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KB, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Russell Localio A, Lo Re V 3rd. Increased risk of hip fracture associated with dually treated HIV/hepatitis B virus coinfection. Journal of Viral Hepatitis. 2015 Nov;22(11):936-47. doi: 10.1111/jvh.12398

Byrne DD, Rosenbach MA, Hamilton KW. Case 4.9: Take One's Breath Away. In: P.H. Chandrasekar ed. Infections in the Immunosuppressed Patient. Oxford University Press; 2016:318-321.

Byrne D, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KBF, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio AR, Lo Re III V. Increased Risk of Hip Fracture Associated with Dually-Treated HIV/Hepatitis B Virus Coinfection [Published online ahead of print March 6, 2015]. J Viral Hepat. 2015 Nov;22(11):936-47. doi: 10.1111/jvh.12398.